Midazolam Injection Recalled Due to Lack of Sterility Assurance
SterRx is recalling Midazolam in 0.9% Sodium Chloride Injection nationwide due to lack of assurance of sterility. The recall affects approximately 36,360 bags distributed across the United States.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: This is an FDA Class II recall of a sterile injectable drug product. Lack of sterility assurance in a parenteral medication poses a significant risk of infection and serious harm to patients who receive the contaminated product, meeting the Severe severity threshold for Class II recalls with risk of serious injury.
Plain-English summary
SterRx, LLC is recalling Midazolam in 0.9% Sodium Chloride Injection, 100 mg per 100 mL (1 mg per mL), NDC 70324-102-02, due to lack of assurance of sterility. The product is a prescription medication manufactured by SterRx located at 141 Idaho Ave., Plattsburgh, NY 12903.
Approximately 36,360 bags have been distributed nationwide across the United States. The affected lot codes and dates span from November 12, 2021, through April 15, 2022, and include multiple production batches with codes such as S21065/BQA through S21385/CBS.
Patients and healthcare providers who have this product in their possession should not use it and should contact their supplier for return and replacement instructions. Healthcare facilities should check their inventory for affected lot codes and quarantine any units matching the recalled batches.
The recalled product
- Product
- Midazolam in 0.9% Sodium Chloride Injection, 100 mg per 100 mL (1 mg per mL), Rx only, SterRx, 141 Idaho Ave., Plattsburgh, NY 12903, NDC 70324-102-02.
- Manufacturer
- SterRx, LLC
- Category
- Drug — Injectable / Parenteral
- Hazard
- lack-of-sterility
- contamination-risk
- infection-risk
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- ModerateGas-X Simethicone 125 mg softgels recall for incomplete labeling
FDA (Drugs) · 2026-05-27
- ModerateVitamin B-Complex, Vitamin C & Folic Acid Dietary Supplement Oral Liquid
FDA (Drugs) · 2026-05-27